ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment

Executive Summary

• ZYUS Life Sciences closed the first tranche of its non‑brokered private placement, issuing 1,923,077 units at $0.65 each for gross proceeds of approximately $1.250 M.
• The company also issued a total of 7,246,376 common share purchase warrants in connection with related‑party loan arrangements (independent director and 102 Sask), each exercisable at $0.69 per share and expiring October 31 2027.
• Proceeds are earmarked for general corporate and working‑capital purposes; the offering received conditional TSXV approval and is subject to a hold period until March 7 2026.

Key Details

• Units Offered: Up to 2,307,692 units; first tranche comprised 1,923,077 units.
• Unit Price: $0.65 per unit.
• Gross Proceeds (First Tranche): Approximately $1,250,000.50 (up to $1.5 M total if full tranche sold).
• Unit Composition: 1 common share + 1 warrant per unit.
• Warrant Terms (Units): Right to purchase one additional common share at $0.95 for 24 months, with acceleration if TSXV price > $3.00 for five consecutive days.
• Related‑Party Warrants – Independent Director Loans: 2,898,550 warrants issued; exercise price $0.69, expiry Oct 31 2027, hold period until Mar 7 2026.
• Related‑Party Warrants – 102 Sask Loan Amendment: 4,347,826 warrants issued; same $0.69 exercise price and expiry/hold terms as above.
• Use of Proceeds: General corporate and working‑capital purposes; no finder’s fees paid.
• Regulatory Status: Offering conducted under prospectus exemptions; conditional TSXV approval received; final acceptance pending. All securities subject to a hold period expiring Mar 7 2026.
• Related Party Transaction Compliance: Exemptions relied upon under MI 61‑101 sections 5.5(b) and 5.7(1)(a); approvals obtained from TSXV.

Notable Quotes

(No executive quotes were included in the release.)